API Board opens doors to Wesfarmers.

Retail conglomerate, Wesfarmers Limited, is stepping up its pursuit of pharmacy wholesaler, Australian Pharmaceutical Industries (API), with a revised $1.55 per share bid.

The move comes less than two months after the API Board knocked back an initial offer which it said fell significantly short of the market rate. 

However, in a statement to the Australian Securities Exchange, this morning API said “it is in the interests of API’s shareholders to progress the revised indicative proposal and allow Wesfarmers to undertake confirmatory due diligence”.

API CEO, Richard Vincent said the revised offer “better reflects the strength and potential of our stable of businesses”, which includes pharmacy brands, Priceline Pharmacy, Soul Pattinson Chemist and Pharmacist Advice.

Under the new proposal, API and Wesfarmers have entered into a Process Deed, under which Wesfarmers has been granted until 16 Oct to undertake confirmatory due diligence to facilitate a binding offer.

See today’s edition of Pharmacy Daily for more. 

advertimg.png

This Pharmacy Daily breaking news is brought to you by  JPH Group

To ensure you continue to receive email from Pharmacy Daily reliably please add info@pharmacydaily.com.au to your 'Safe Senders' list and set images to always display.

To forward this email to a friend click here.  To receive your own copy of Pharmacy Daily sign up here.
To modify subscription details click here.  To unsubscribe click here.

facebook.com/pharmacydaily  Follow us on Instagram  PD on LinkedIn  Follow us on Twitter  Pharmacy Daily TV

The Therapeutic Goods Advertising Code 2015 requires strict compliance. View the code here.

Pharmacy Daily - a division of Business Publishing Group
PO Box 1010 Epping NSW Australia 1710
Level 2, Suite 1 64 Talavera Rd Macquarie Park NSW 2113
Phone: 1300 799 220 ( 61 2 8007 6760)
Email: info@pharmacydaily.com.au